Nanosizing — Oral formulation development and biopharmaceutical evaluation

Poor aqueous solubility represents a major hurdle in achieving adequate oral bioavailability for a large percentage of drug compounds in drug development nowadays. Nanosizing refers to the reduction of the active pharmaceutical ingredient (API) particle size down to the sub-micron range, with the fi...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2007-07, Vol.59 (7), p.631-644
Main Authors: Kesisoglou, Filippos, Panmai, Santipharp, Wu, Yunhui
Format: Article
Language:English
Subjects:
Animals
Bioavailability enhancement
Chemistry, Pharmaceutical
Dissolution
Drug Compounding - methods
Drug Evaluation - methods
Formulation
Humans
Nanoparticle
Nanoparticles
Nanosizing
Nanosuspension
Nanotechnology - methods
Particle Size
Pharmaceutical Preparations - administration & dosage
Pharmaceutical Preparations - chemistry
Pharmacokinetics
Pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Poor aqueous solubility represents a major hurdle in achieving adequate oral bioavailability for a large percentage of drug compounds in drug development nowadays. Nanosizing refers to the reduction of the active pharmaceutical ingredient (API) particle size down to the sub-micron range, with the final particle size typically being 100–200 nm. The reduction of particle size leads to a significant increase in the dissolution rate of the API, which in turn can lead to substantial increases in bioavailability. This review describes the principles behind nanosizing, the production and characterization of nanoformulations as well as the current experience with utilization of such formulations in vivo.
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2007.05.003